ROR2 and renal carcinoma: Although it would have been preferable to confirm the effects on proliferation, migration and invasion using a second independent siRNA, our results are consistent with the pro-migratory, pro-invasive phenotype reported for ROR2 in melanoma, ovarian and renal cancer cells [28, 32, 33], and suggest that ROR2 is functioning as predicted in the context of the introduced BRAFV600E mutation.